Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Public ClinicalTrials.gov record NCT05821088. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Study identification
- NCT ID
- NCT05821088
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- David Bond, MD
- Other
- Enrollment
- 37 participants
Conditions and interventions
Conditions
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Grade 3b Follicular Lymphoma
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
- Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
- Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Refractory Grade 3b Follicular Lymphoma
- Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified
- Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
- Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
- Biopsy Procedure
- Biospecimen Collection Procedure
- Carboplatin Drug
- Computed Tomography Procedure
- Etoposide Drug
- Ifosfamide Drug
- Lenalidomide Drug
- Positron Emission Tomography Procedure
- Tafasitamab Biological
Procedure · Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 28, 2023
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2026
- Last update posted
- Nov 19, 2025
2023 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05821088, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2025 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05821088 live on ClinicalTrials.gov.